Disciplined Investors L.L.C. Buys New Position in Novo Nordisk A/S $NVO

Disciplined Investors L.L.C. bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, HoldingsChannel.com reports. The fund bought 20,233 shares of the company’s stock, valued at approximately $1,029,000.

Other hedge funds also recently modified their holdings of the company. Smith Chas P & Associates PA Cpas boosted its position in Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC boosted its position in Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares during the last quarter. Quantbot Technologies LP purchased a new position in Novo Nordisk A/S in the third quarter worth $3,171,000. Romano Brothers AND Company boosted its position in Novo Nordisk A/S by 704.0% in the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock worth $1,742,000 after purchasing an additional 29,978 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Novo Nordisk A/S in the third quarter worth $19,519,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $42.06 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The firm has a market cap of $187.78 billion, a price-to-earnings ratio of 9.87, a PEG ratio of 3.83 and a beta of 0.78. The business’s fifty day moving average is $41.35 and its 200 day moving average is $46.24.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Research analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on NVO. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research note on Tuesday, March 3rd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Finally, Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched the Wegovy pill in the UAE, marking its first market outside the U.S. and signaling the start of a broader international rollout for its obesity franchise. Reuters article
• Positive Sentiment: Novi Health announced a partnership with Novo Nordisk to expand structured weight-care support in Singapore, which could help improve patient access and treatment adoption in another growth market. Yahoo Finance article
• Positive Sentiment: Danske Bank raised Denmark’s GDP forecast to 3.7%, citing export strength supported by demand for Novo Nordisk products, underscoring the company’s importance to the Danish economy. Financial Post article
• Neutral Sentiment: Commentary suggested there may be “light at the end of the tunnel” for Novo Nordisk, but it was opinion-based rather than a new fundamental update. Motley Fool article
• Negative Sentiment: Eli Lilly won back CVS Health, reversing part of Novo Nordisk’s advantage in GLP-1 access and highlighting intensifying competition in the obesity drug market. MarketBeat article
• Negative Sentiment: ASML’s surge to record valuation drew attention to Novo Nordisk’s prior peak as Europe’s most valuable stock, reinforcing how far NVO has fallen from its high-water mark. Yahoo Finance article

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.